Topic

Jeremy (“Jerry”) V. Gross is the chief executive officer and co-founder at 

, a healthcare technology company. As CEO, Jerry is responsible for overseeing the vision, strategy, and growth of the company as well as its newly launched platform-as-a-service, VytalOS, which offers consumers frictionless prescription management and delivery. Jerry has 30+ years of experience leading development teams and leveraging emerging technologies to create disruptive innovation within biopharma, healthcare, and the financial technology industries.

Articles

Soaring prescription drug costs and access to healthcare are two of the industry’s primary challenges. But with the widespread acceptance and adoption of new healthcare technologies, many pharma and health tech companies are stepping up to address these issues.

How Health Tech Companies are Democratizing the Pharma Industry

Richard Pops serves as Chairman and Chief Executive Officer of Alkermes, a fully-integrated, global biopharmaceutical company developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer.

With the headlines focused on COVID-19, many may have forgotten about the escalating epidemic of substance use disorder. National Recovery Month is a time to bring this issue back to the top of the agenda, raise awareness, and drive action, writes Richard Pops, CEO of Alkermes.

National Recovery Month is a Time for Action

. Kate Beale is a senior policy director in Crowell & Moring's Government Affairs Group and affiliated with C&M International.

What can both public and private sector stakeholders learn from current trends to accelerate innovation around the COVID-19 pandemic and other emerging global health threats, including antimicrobial resistance?

Advancing Health Innovation in 2022: Where Should We Focus?

Pharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.

Purposeful Partnerships for Post-COVID Era

What are the reasons behind the slump and what does the future hold?

After Blowout 2020, Biotech Worst Performing Sector YTD

Brent Vaughan is CEO, Cognito Therapeutics.

The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.

Moving Beyond Traditional Approaches to Alzheimer’s Disease 

Dr. Andrea Pfeifer is Chief Executive Officer and co-founder of AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases.

Dr. William Mobley is Distinguished Professor of Neurosciences at UC San Diego, where his laboratory studies the biology of Down syndrome, in particular the emergence of Alzheimer disease. He served as a site principal investigator in the recently completed AC Immune-sponsored vaccination trial in people with Down syndrome.

It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.

Are We Forgetting to Develop Vaccines for Diseases other than COVID?

Ethics and diversity on full display across pharma industry.

The Power of Parity

Not to be outdone by the showbiz industry, Pharm Exec's own awards season is fast approaching. 

Awards Season in Bloom

Embracing the new, holistic views of pharma in 2021.

Opinion